OncoSec Medical Incorporated (ONCS)
Stock Price:
$4.40 USD
0.20 (4.76%)
Updated Aug 3, 2020 1:51 PM EDT - Market open
Key Info
| Market Cap |
101.34M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-40.78M |
| Shares Out |
23.03M |
| EPS (ttm) |
-3.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$4.40 |
| Previous Close |
$4.20 |
| Change ($) |
0.20 |
| Change (%) |
4.76% |
| Day's Open |
4.18 |
| Day's Range |
4.11 - 4.54 |
| Day's Volume |
310,481 |
| 52-Week Range |
1.04 - 4.89 |
More Stats
| Market Cap |
101.34M |
| Enterprise Value |
78.79M |
| Earnings Date (est) |
Dec 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.03M |
| Float |
9.18M |
| EPS (basic) |
-3.22 |
| EPS (diluted) |
-3.08 |
| FCF / Share |
-1.45 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
92,949 |
| Short Ratio |
0.48 |
| Short % of Float |
1.51% |
| Beta |
2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.46 |
| Revenue |
n/a |
| Operating Income |
-40.43M |
| Net Income |
-40.78M |
| Free Cash Flow |
-31.88M |
| Net Cash |
22.55M |
| Net Cash / Share |
0.98 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-76.22% |
| ROE |
-190.23% |
| ROIC |
-1,229.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.10*
(61.36% upside)
Low
5.00
Current: $4.40
High
10.00
Target: 7.10
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -29.98 | -36.61 | -21.45 | -26.89 | -21.24 | -11.95 | -7.06 | -5.53 | -1.70 | -0.04 |
| Net Income | -30.28 | -39.14 | -21.45 | -26.89 | -21.24 | -12.01 | -7.15 | -2.36 | -3.76 | -0.04 |
| Shares Outstanding | 7.05 | 4.01 | 2.02 | 1.65 | 1.27 | 0.95 | 0.53 | 0.34 | 0.32 | 0.34 |
| Earnings Per Share | -4.29 | -9.75 | -10.60 | -16.30 | -16.70 | -12.60 | -13.40 | -8.00 | -12.00 | - |
| Operating Cash Flow | -29.00 | -23.22 | -17.34 | -17.81 | -17.65 | -8.98 | -5.53 | -4.22 | -1.31 | -0.01 |
| Capital Expenditures | -0.01 | -0.07 | -0.02 | -1.55 | -1.43 | -0.51 | -0.11 | -0.05 | -0.31 | - |
| Free Cash Flow | -29.01 | -23.29 | -17.36 | -19.36 | -19.08 | -9.49 | -5.65 | -4.27 | -1.62 | -0.01 |
| Cash & Equivalents | 25.15 | 26.98 | 11.44 | 28.75 | 32.04 | 37.85 | 4.97 | 5.14 | 2.46 | 0.00 |
| Total Debt | 0.08 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 25.06 | 26.98 | 11.44 | 28.75 | 32.04 | 37.85 | 4.97 | 5.14 | 2.46 | 0.00 |
| Assets | 29.89 | 30.25 | 15.23 | 32.41 | 35.59 | 39.39 | 6.51 | 7.43 | 5.67 | - |
| Liabilities | 5.61 | 7.32 | 4.54 | 4.35 | 2.89 | 1.32 | 1.77 | 3.00 | 8.04 | 0.03 |
| Book Value | 24.28 | 22.92 | 10.70 | 28.05 | 32.70 | 38.07 | 4.74 | 4.43 | -2.36 | -0.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
OncoSec Medical Incorporated |
| Country |
United States |
| Employees |
37 |
| CEO |
Daniel J. O'Connor |
Stock Information
| Ticker Symbol |
ONCS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ONCS |
Description
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the Phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company is developing new DNA-encoded therapeutic candidates and tumor indications. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a collaborative research agreement with Duke University School of Medicine to evaluate TAVOPLUS; a collaboration with Dana-Farber Cancer Institute and the Marasco Laboratory to develop CAR T-cell therapies for triple-negative breast cancer and ovarian cancer; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and TAVO; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.